

**Kyowa Hakko Kirin Co., Ltd.****Appendix to the Fiscal 2011 First Quarter Consolidated Financial Statements**

First quarter results for Fiscal 2011  
(January 1, 2011 - March 31, 2011)

<b>Index</b>	<b>Page</b>
I. Consolidated Financial results	
1. Income	1
2. Results by segment	1
3. Other income	2
4. Extraordinary income/losses	2
5. R&D expenses	2
6. Capital expenditure (tangible fixed assets)	3
7. Depreciation expenses	3
8. Employee numbers	3
9. Key indicators	3
II. Consolidated Subsidiaries and affiliates	4
III. Non-Consolidated Net sales by division	
1. Kyowa Hakko Kirin	5
2. Kyowa Hakko Bio	6
3. Kyowa Hakko Chemical	6
R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the first quarter of Fiscal 2011, the three-month period from January 1, 2011 to March 31, 2011. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

## I. Consolidated Financial Results

### 1. Trends in income

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results			FY 2011 forecasts	
	January 1 to March 31 (A)	January 1 to June 30	January 1 to December 31	January 1 to March 31 (B)	Change on January to March 2010		January 1 to June 30	January 1 to December 31,
					Amount (B-A)	% (B/A)		
<b>Net sales</b>	99,256	203,466	413,738	114,862	15,605	116%	175,000	325,000
<b>Gross Profit</b>	44,100	92,763	190,979	56,644	12,543	128%	--	--
Selling, general and administrative expenses	32,572	71,071	145,568	34,734	2,161	107%	--	--
<b>Operating income (prior to amortization of goodwill)</b>	13,853	26,344	54,713	24,235	10,382	175%	24,639	46,267
<b>Operating income</b>	11,527	21,692	45,410	21,909	10,382	190%	20,000	37,000
Other income	963	3,120	5,201	1,280	316		--	--
Other expenses	550	2,478	4,111	937	386		--	--
<b>Ordinary income</b>	11,940	22,334	46,500	22,252	10,311	186%	20,500	38,000
Extraordinary income	--	1,082	2,822	8,265	8,265		--	--
Extraordinary expenses	577	5,775	7,023	3,214	2,636		--	--
<b>Net income before income taxes</b>	11,363	17,641	42,299	27,304	15,940	240%	28,000	45,500
Corporate, local and enterprise taxes	5,366	7,718	20,040	12,496	7,129		--	--
Income from minority interests	(57)	21	61	22	79		--	--
<b>Net income</b>	6,053	9,901	22,197	14,785	8,731	244%	14,500	25,500
EPS before goodwill amortization (¥/share)	14.71	25.55	55.29	30.03			33.59	61.02

Note: No revisions have been made to the consolidated results forecasts announced January 28, 2011. Due to the impact of the Great East Japan Earthquake that struck March 11, 2011, on Group results, it is difficult to make reasonable results forecasts at this stage.

### 2. Trends in results by segment

#### (1) Results by operating segment

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results			FY 2011 forecasts	
	January 1 to March 31 (A)	January 1 to June 30	January 1 to December 31	January 1 to March 31 (B)	Change on January to March 2010		January 1 to June 30	January 1 to December 31
					Amount (B-A)	% (B/A)		
<b>Net sales</b>	99,256	203,466	413,738	114,862	15,605	116%	175,000	325,000
Pharmaceuticals	49,674	103,475	210,362	63,393	13,719	128%	105,000	212,000
Bio-Chemicals	22,213	44,186	84,236	19,686	(2,526)	89%	40,000	80,000
Chemicals	30,281	61,289	130,018	33,550	3,268	111%	31,000	31,000
Other	2,493	5,082	10,499	2,651	157	106%	5,000	10,000
Total	104,662	214,034	435,116	119,281	14,619	114%	181,000	333,000
Eliminations	(5,406)	(10,567)	(21,377)	(4,419)	986	82%	(6,000)	(8,000)
<b>Operating income</b>	11,527	21,692	45,410	21,909	10,382	190%	20,000	37,000
<i>*Before goodwill amortization</i>	13,853	26,344	54,713	24,235	10,382	175%	24,639	46,267
Pharmaceuticals	9,678	17,993	35,857	18,419	8,740	190%	16,500	32,000
Bio-Chemicals	11,835	22,307	44,485	20,576	8,740	174%	20,814	40,629
Chemicals	1,010	1,853	3,275	1,272	261	126%	1,800	3,000
Other	1,166	2,166	3,901	1,428	261	122%	2,113	3,626
Chemicals	674	1,589	5,678	2,135	1,461	317%	1,500	1,500
Other	686	1,614	5,728	2,147	1,461	313%	1,512	1,512
Other	82	150	363	82	0	100%	200	500
Other	82	150	363	82	-0	100%	200	500
Total	11,446	21,587	45,175	21,909	10,463	191%	20,000	37,000
Eliminations	13,772	26,239	54,478	24,235	10,463	176%	24,639	46,267
Eliminations	81	105	235	0	(81)	0%	--	--

#### Notes:

- Figures representing amounts before goodwill amortization have been italicized.
- As of the period under review, Kyowa Hakko Kirin has adopted "Accounting Standards Related to the Disclosure of Segment Information". Since the segment classification methods used to classify business by segment are the same as those used previously, we are able to make comparisons with the previous year.
- The Chemicals Business will discontinued at the end of the first quarter following the transfer of all shares of Kyowa Hakko Chemical on March 31, 2011. As a result, income from Chemicals will be consolidated on the Statements of Income until March 31, 2011.

## (2) Overseas sales

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results						FY 2011 results	
	January 1 to March 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales	January 1 to March 31	Percentage of consolidated sales
<b>Japan</b>	79,301	79.9%	161,229	79.2%	328,596	79.4%	91,329	79.5%
<b>Overseas sales</b>	19,955	20.1%	42,236	20.8%	85,141	20.6%	23,532	20.5%
America	5,162	5.2%	12,977	6.4%	23,467	5.7%	6,837	6.0%
Europe	5,687	5.7%	10,779	5.3%	21,477	5.2%	6,060	5.3%
Asia	8,991	9.1%	18,114	8.9%	39,689	9.6%	10,499	9.1%
Other regions	113	0.1%	364	0.2%	507	0.1%	135	0.1%
<b>Total consolidated net sales</b>	<b>99,256</b>	<b>100.0%</b>	<b>203,466</b>	<b>100.0%</b>	<b>413,738</b>	<b>100.0%</b>	<b>114,862</b>	<b>100.0%</b>

## 3. Trends in other income

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31
<b>Other income</b>	963	3,120	5,201	1,280
Interest received	97	221	362	65
Dividend income	49	485	844	57
Foreign exchange gain	36	--	--	579
Income from equity method investments	337	626	1,074	166
Other	442	1,787	2,920	411
<b>Other expenses</b>	550	2,478	4,111	937
Interest expense	69	122	199	43
Foreign exchange loss	--	1,143	1,280	--
Loss from revaluation of derivatives	--	--	--	431
Loss from disposal of fixed assets	243	608	1,493	165
Other	237	604	1,138	296

## 4. Trends in extraordinary income / losses

Millions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31
<b>Extraordinary income</b>	--	1,082	2,822	8,265
Gain on sale of shares in affiliates	--	--	--	8,265
Gain on sale of investment securities	--	120	1,828	--
Gain on occurrence of negative goodwill	--	854	854	--
Allowance for doubtful accounts	--	107	139	--
<b>Extraordinary losses</b>	577	5,775	7,023	3,214
Loss from revaluation of investment securities	--	2,588	1,473	1,546
Advisory expenses	--	--	--	973
Effect from application of asset retirement obligation standards	--	--	--	447
Allowance for reserve for points from previous years	--	--	--	128
Casualty loss	--	--	--	118
Loss on revisions to retirement benefit system	577	1,771	1,771	--
Asset impairment losses	--	--	1,374	--
Extraordinary depreciation of fixed assets	--	1,225	1,225	--
Provision for environmental measures	--	--	887	--
Other	--	189	290	--

## 5. Trends in R&amp;D expenses

Billions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results	FY 2011 forecasts	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
<b>R&amp;D (Consolidated)</b>	9.1	21.4	44.2	10.8	24.0	50.3
R&D to net sales ratio (%)	9.2%	10.5%	10.7%	9.4%	13.7%	15.5%
Pharmaceuticals	8.1	19.3	40.0	9.8	21.9	46.5
(R&D to net sales ratio) (%)	16.4%	18.7%	19.0%	15.6%	20.9%	21.9%
Bio-Chemicals	0.7	1.5	3.2	0.7	1.8	3.5
Chemicals	0.2	0.4	1.0	0.2	0.3	0.3
Other	--	--	--	--	--	--

## 6. Trends in capital expenditure

Billions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results	FY 2011 forecasts	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
<b>Capital expenditure (Consolidated)</b>	5.5	12.2	21.9	3.1	10.2	18.9
Pharmaceuticals	4.3	7.0	11.7	1.4	5.1	8.6
Bio-Chemicals	0.9	3.7	7.5	1.3	4.8	10.0
Chemicals	0.2	1.3	2.5	0.3	0.3	0.3
Other	0.0	0.0	0.0	0.0	0.0	0.0

## 7. Trends in depreciation expenses

Billions of yen, rounded down

	January 1, 2010 to December 31, 2010 results			FY 2011 results	FY 2011 forecasts	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
<b>Depreciation expenses (Consolidated)</b>	4.2	10.5	22.1	5.5	10.7	21.8
Pharmaceuticals	1.9	4.5	10.7	3.3	6.9	14.3
Bio-Chemicals	1.2	3.8	6.7	1.2	2.8	6.5
Chemicals	1.0	2.1	4.6	0.9	1.0	1.0
Other	0.0	0.0	0.0	0.0	0.0	0.0

## 8. Employee numbers

	January 1, 2010 to December 31, 2010			FY 2011
	March 31	June 30	December 31	March 31
<b>Employee numbers (Consolidated)</b>	7,362	7,554	7,484	6,818
Pharmaceuticals			5,041	
Bio-Chemicals			1,581	
Chemicals			652	
Other			210	

## 9. Trends in key indicators

### (1) Exchange rate

	January 1, 2010 to December 31, 2010 results			FY 2011 results	FY 2011 forecasts	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
US Dollar (¥/US\$)	91	91	88	82	84	84
Euro (¥/Euro)	126	121	116	113	111	111

### (2) Operating indicators (Consolidated)

	January 1 to December 31, 2010 results			FY 2011 results
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31
(prior to amortization of goodwill)	14.71	25.55	55.29	30.03
Net income per share (yen)	10.63	17.38	38.96	25.95
Operating income to sales ratio (%)	11.6%	10.7%	11.0%	19.1%
Total assets (million yen)	684,773	679,685	695,862	665,552
Net assets (million yen)	542,837	540,565	544,992	554,882
Equity ratio (%)	78.7%	79.4%	78.2%	83.2%
Net assets per share (yen)	946.72	946.77	954.58	971.89
Number of staff at end of term	7,362	7,554	7,484	6,818

## II. Subsidiaries and affiliates

(As of March 31, 2011)

Segment	Type	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
		Kirin Kunpeng (China) Bio- Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)
		Kyowa Medical Promotion Co., Ltd.	100.0%	Sales promotion of pharmaceuticals
		Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology (US)
		Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)
		Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
		Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
		Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
		Kyowa Hakko Kirin Italia S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
		Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)
		Kyowa Kirin Pharmaceuticals (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
		Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong Kong)
Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)		
Bio-Chemicals	Consolidated subsidiary	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
		Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
		Biokyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
		Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
		Kyowa Hakko Europe GmbH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
		Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)
		Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Singapore)
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
		Shinwa Pharmaceutical Co., Ltd.	100.0%	Sale of herbal medicines and health foods
Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment		
Other	Consolidated subsidiary	Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.
	Affiliate accounted for by the equity method	Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Notes: 1. Changes to the scope of consolidation

Removed: Three companies: Kashiwagi Corporation (\*1), Kyowa Hakko Chemical Co., Ltd.(\*2), Miyako Kagaku Co., Ltd.(\*2)

\* 1. As of January 1, 2011, Kashiwagi Corporation was merged with Miyako Kagaku Co., Ltd. and eliminated.

\* 2. Kyowa Hakko Chemical Co., Ltd. and its subsidiary Miyako Kagaku Co., Ltd. will be removed from the scope of consolidation at the end of the first quarter of the current period and all shares of Kyowa Hakko Chemical Co., Ltd. will be transferred to KJ Holdings Inc. on March 31, 2011.

### III. Net sales by division (Items and main products)

#### 1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	Fiscal period to December 31, 2010			Fiscal 2011 results		FY2011 forecasts	
	January 1 to March 31 results (A)	January 1 to June 30 results	January 1 to December 31 results	January 1 to March 31 results (B)	Change on January 1 to March 31 (B/A)	January 1 to June 30	January 1 to December 31
<b>Pharmaceuticals division total</b>	<b>45.3</b>	<b>94.1</b>	<b>192.9</b>	<b>59.8</b>	<b>132%</b>	<b>97.6</b>	<b>195.6</b>
<b>Indication / Product</b>							
<i>ESA formulation</i> <b>Nesp</b>	7.7	17.7	41.7	11.9	154%	22.9	46.9
<i>ESA formulation</i> <b>Espo</b>	2.7	5.7	10.8	1.3	51%	2.1	4.0
<b>Nesp/Espo</b>	10.3	23.4	52.6	13.3	130%	25.0	50.9
<i>Secondary hyperparathyroidism</i> <b>Regpara</b>	1.9	4.3	9.5	2.5	129%	5.3	11.1
<i>Antiallergenic</i> <b>Allelock</b>	8.2	13.9	26.8	13.7	168%	16.8	29.8
<i>Antiallergenic</i> <b>Celtect</b>	0.7	1.4	2.7	0.7	106%	1.3	2.4
<i>Antiallergic eyedrops</i> <b>Patanol</b>	3.5	4.7	7.5	7.3	204%	7.2	10.2
<i>G-CSF</i> <b>Gran/Neu-up*1</b>	3.3	7.3	14.4	3.3	99%	6.7	14.5
<i>Cancer pain</i> <b>Fentos*2</b>	--	0.0	0.8	0.4	-	0.9	2.4
<i>Anticancer</i> <b>Farmorubicin*3 / Adriacin</b>	1.1	2.4	4.8	0.2	24%		
<i>Anticancer</i> <b>5 – FU</b>	0.7	1.5	3.1	0.7	98%	1.4	2.7
<i>Anticancer</i> <b>Navelbine</b>	0.5	1.0	2.0	0.4	87%	0.8	1.6
<i>Cardiovascular</i> <b>Coniel</b>	4.8	10.3	21.0	4.6	97%	9.8	19.9
<i>Cardiovascular (Hypertension)</i> <b>Coversyl</b>	0.9	2.0	4.2	0.9	100%	1.9	3.9
<i>Cardiovascular</i> <b>Inovan / Pre Dopa</b>	0.7	1.5	3.0	0.7	99%	1.4	2.9
<i>Antiepileptic</i> <b>Depakene</b>	2.3	5.2	11.0	2.6	114%	5.3	11.0
<i>Parkinson's disease</i> <b>Permax*4</b>	--	0.7	2.0	0.5	-	1.1	2.3
<i>Gastrointestinal</i> <b>Nauzelin</b>	1.3	2.6	5.3	1.2	90%	2.4	5.0
<i>Inflammatory bowel disease</i> <b>Asacol</b>	0.0	0.2	0.7	0.5	751%	1.0	2.6
<b>Exports and Technology Out-Licensing</b>	<b>5.5</b>	<b>13.1</b>	<b>24.1</b>	<b>7.6</b>	<b>140%</b>	<b>11.8</b>	<b>23.9</b>

Notes 1: As of March 1, 2010, manufacturing, sales and other rights for Neu-up were transferred to Yakult Honsha.  
Therefore, Gran/Neu-up figures after March 31, 2010 include only sales figures for Gran.

2: Sales of Fentos began June 24, 2010.

3: Sales of Farmorubicin ended December 31, 2010 following completion of our contract with Pfizer.  
Therefore, as of January 2011, only amounts for Adriacin will be included in Farmorubicin/Adriacin.

4: Sales of Permax began April 1, 2010.

## 2. Kyowa Hakko Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	January 1, 2010 to December 31, 2010 results			FY 2011 results		FY 2011 forecasts	
	January 1 to March 31 (A)	January 1 to June 30	January 1 to December 31	January 1 to March 31 (B)	Change on January to March 2010 (B/A)	January 1 to June 30	January 1 to December 31
<b>Bio-Chemical division total</b>	14.8	28.7	54.2	12.3	83%	25.8	51.0
<b>Pharmaceuticals / Industrial raw materials</b>							
<b>Amino acids</b>	5.5	10.8	20.4	4.5	83%	9.8	19.3
<b>Nucleic acids and vitamins</b>	1.3	2.5	4.8	1.2	97%	2.4	4.8
<b>Other</b>	2.1	3.9	8.0	1.7	84%	3.6	7.7
<b>Health care products</b>	2.3	4.9	9.8	2.1	93%	5.0	9.9

## 3. Kyowa Hakko Chemical

Billions of yen, rounded down

Chemicals division (non-consolidated)	January 1, 2010 to December 31, 2010 results			FY 2011 results		FY 2011 forecasts	
	January 1 to March 31 (A)	January 1 to June 30	January 1 to December 31	January 1 to March 31 (B)	Change on January to March 2010 (B/A)	January 1 to June 30	January 1 to December 31
<b>Chemicals division total</b>	19.3	39.7	85.7	22.9	118%	21.1	21.1
<b>Solvents</b>	7.4	15.9	33.4	8.4	113%	8.0	8.0
<b>Raw materials for plasticizers</b>	6.3	12.2	27.7	7.7	122%	7.1	7.1
<b>Specialty chemicals</b>	4.6	9.9	21.2	5.9	128%	5.3	5.3

Note: No revisions have been made to the consolidated results forecasts announced January 28, 2011. Due to the impact of the Great East Japan Earthquake that struck March 11, 2011, on Group results, it is difficult to make reasonable results forecasts at this stage.

R&D PIPELINES

Filed • Approved

Apr 27th 2011

Therapeutic area	Code Name Generic Name	Mechanism of action	Stage		Indication	Formulation	In-house or Licensed	Remarks
			Japan	Other countries				
Oncology	<b>KW-0761</b>	Anti-CCR4 humanized antibody	Filed Apr/2011		Adult T-cell leukemia-lymphoma	Injection	Developed In-house	(株) POTELLIGENT®
	<b>KRN321</b> Darbepoetin Alfa	Long-acting Erythropoiesis stimulating agent	Filed Nov/2008		☆: Chemotherapy induced anemia	Injection	Kirin-Amgen	Launched for anemia of CKD patients
	<b>Pegfilgrastim</b>	Long-acting Granulocyte colony stimulating factor		Filed in Asia	Chemotherapy induced febrile neutropenia	Injection	Kirin-Amgen	Asia: Korea, Taiwan and Vietnam
Nephrology	<b>Cinacalcet Hydrochloride</b>	Calcium receptor agonist		Filed in Singapore	Secondary hyperparathyroidism	Oral	Licensed from NPS	Japan: Launched
	<b>Darbepoetin Alfa</b>	Long-acting Erythropoiesis stimulating agent		Filed in Asia	Renal Anemia (on dialysis)	Injection	Kirin-Amgen	Asia: Singapore, Thailand and Philippines
Other	<b>AMG531</b> Romiplostim	Thrombopoietin receptor agonist	Release Apr/2011	Filed in Asia	Idiopathic (Immune) thrombocytopenic purpura	Injection	Kirin-Amgen	Asia: Korea, Singapore, Hong Kong and Malaysia

Phase II • Phase III

Therapeutic area	Code Name Generic Name	Mechanism of action	Stage		Indication	Formulation	In-house or Licensed	Remarks
			Japan	Other countries				
Oncology	<b>KW-0761</b>	Anti-CCR4 humanized antibody		Phase I / II in USA	Peripheral T-cell lymphoma and cutaneous T-cell lymphoma	Injection	Developed In-house	(株) POTELLIGENT®
			Phase II		Adult T-cell leukemia-lymphoma, Ado-on therapy (for untreated patients)			
			Phase II		Peripheral T/NK-cell Lymphoma			
	<b>KW-2246</b> Fentanyl citrate	μ-opioid receptor agonist	Phase III		Cancer pain	Sublingual tablet	Licensed from Orexo	
	<b>KRN125</b> Pegfilgrastim	Long-acting Granulocyte colony stimulating factor	Phase III		Chemotherapy induced febrile neutropenia	Injection	Kirin-Amgen	
	<b>ARQ 197</b>	c-Met inhibitor	Phase II	Phase II in Korea	Gastric cancer	Oral	Licensed from ArQule.	
<b>KW-2478</b>	HSP90 inhibitor	Phase I		Lung cancer				
Nephrology	<b>KRN321</b> Darbepoetin Alfa	Long-acting Erythropoiesis stimulating agent	Phase III		☆: Paediatric Renal Anemia	Injection	Kirin-Amgen	Launched in Japan for anemia of CKD patients
	<b>Cinacalcet Hydrochloride</b>	Calcium receptor agonist		Phase II in China	Renal Anemia (on dialysis)			
Immunology/Allergy	<b>ASKP1240</b>	Anti-CD40 fully human monoclonal antibody	Phase I	Phase II in USA	Organ transplant rejection	Injection	Developed In-house	Jointly developed with Astellas
	<b>Z-206</b> Mesalazine	pH dependent controlled release tablet	Phase II		☆: Crohn's disease	Oral	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma Launched in Japan for ulcerative colitis from December, 2009.
CNS	<b>KW-6002</b> Istradefylline	Adenosine A2a receptor antagonist	Phase III		Parkinson's disease	Oral	Developed In-house	Outlicensed to Valeant International SRL (changed from Biovail by merger) for the development and commercialization of KW-6002 in the US and Canada.
	<b>KW-6500</b> Apomorphine Hydrochloride	Dopamine receptor agonist	Phase III		Parkinson's disease	Injection	Licensed from Britannia Pharmaceuticals Limited	
	<b>KW-6485</b> Topiramate	Antiepileptic drugs	Phase III		☆: Pediatric epilepsy	Oral	Licensed from JANSSEN PHARMACEUTICAL K.K.	Launched in Japan for use as an epileptic drug

Phase I

Therapeutic area	Code Name Generic Name	Mechanism of action	Stage		Indication	Formulation	In-house or Licensed	Remarks
			Japan	Other countries				
Oncology	<b>KW-2450</b>	IGF-1 receptor signal inhibitor		Phase I in USA	Cancer	Oral	Developed In-house	
	<b>KRN330</b>	Anti-A33 fully human antibody		Phase I / II a in USA	Cancer	Injection	Developed In-house	
	<b>BIW-8962</b>	Anti-GM2 humanized antibody		Phase I / II a in USA	Cancer	Injection	Developed In-house	POTELLIGENT®
	<b>KRN51</b> Tivozanib	VEGF receptor inhibitor	Phase I		Cancer	Oral	Developed In-house	
	<b>KHK2866</b>	Anti-HB-EGF humanized antibody		Phase I in USA	Cancer	Injection	Developed In-house	POTELLIGENT®
Nephrology	<b>RTA 402</b> Bardoxolone Methyl	Antioxidant Inflammation Modulator	Phase I		Diabetic nephropathy	Oral	Licensed from Reata	
Immunology/Allergy	<b>KHK4563</b> Benralizumab	Anti-IL-5 receptor humanized antibody	Phase I		Asthma	Injection	Developed In-house	Being developed by MedImmune as MEDI-563 worldwide except in Japan and other Asian countries POTELLIGENT®
Other	<b>KHK6188</b>	Cannabinoid CB2 receptor agonist	Phase I		Neuropathic pain	Oral	Developed In-house	
	<b>KW-3357</b> Anithrombin	Recombinant human antithrombin	Phase I	Phase I in Europe	Disseminated intravascular coagulation, Congenital antithrombin deficiency	Injection	Developed In-house	
	<b>KRN23</b>	Anti-FGF23 fully human antibody		Phase I in USA	X-linked hypophosphatemic rickets/osteomalacia (XLH)	Injection	Developed In-house	

(株) KW-0761 is outlicensed to Amgen Inc. on March 6th, 2008, with an exclusive right to develop and commercialize KW-0761 worldwide, except in Japan, Korea, China and Taiwan. Kyowa Hakko Kirin has retained the development and commercialization rights in these countries. In 2010, KHK paid Amgen US\$20M for the buy-out of Amgen's option to assume the development and commercialization of KW-0761 in oncology setting in Amgen's licensed territory, which was granted under the License Agreement.

Updated since Jan 28th, 2011 (Area, Stage, Filed, Approved, Launched etc.)

★ New indication